A Randomized, Double-Blind, Phase III Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189)
Phase of Trial: Phase III
Latest Information Update: 12 Dec 2017
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Dexamethasone; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-189; MK-3475-189/KEYNOTE-189
- Sponsors Merck Sharp & Dohme
- 30 Nov 2017 Planned number of patients changed from 570 to 646.
- 30 Nov 2017 Status changed from active, no longer recruiting to recruiting.
- 17 Nov 2017 Planned End Date changed from 1 Feb 2019 to 4 Feb 2019.